Ribociclib Improves Progression-Free Survival for Some Women with Metastatic Breast Cancer

A summary of interim results from a phase III trial testing ribociclib plus letrozole (Femara®) as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.